JP2022008474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022008474A5 JP2022008474A5 JP2021153626A JP2021153626A JP2022008474A5 JP 2022008474 A5 JP2022008474 A5 JP 2022008474A5 JP 2021153626 A JP2021153626 A JP 2021153626A JP 2021153626 A JP2021153626 A JP 2021153626A JP 2022008474 A5 JP2022008474 A5 JP 2022008474A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- protoxin
- pain
- isolated
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000844259 Thrixopelma pruriens Beta/omega-theraphotoxin-Tp2a Proteins 0.000 claims 37
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 claims 16
- 102000048004 human SCN9A Human genes 0.000 claims 15
- 208000002193 Pain Diseases 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000003556 assay Methods 0.000 claims 5
- 230000028161 membrane depolarization Effects 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 208000032984 Intraoperative Complications Diseases 0.000 claims 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000004983 Phantom Limb Diseases 0.000 claims 2
- 206010056238 Phantom pain Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 208000002847 Surgical Wound Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000001314 paroxysmal effect Effects 0.000 claims 2
- 210000000578 peripheral nerve Anatomy 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical group CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical group [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142069P | 2015-04-02 | 2015-04-02 | |
| US62/142,069 | 2015-04-02 | ||
| JP2017551164A JP6985151B2 (ja) | 2015-04-02 | 2016-03-31 | プロトキシン−ｉｉ変異体及びその使用方法 |
| PCT/US2016/025247 WO2016161100A1 (en) | 2015-04-02 | 2016-03-31 | Protoxin-ii variants and methods of use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551164A Division JP6985151B2 (ja) | 2015-04-02 | 2016-03-31 | プロトキシン−ｉｉ変異体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022008474A JP2022008474A (ja) | 2022-01-13 |
| JP2022008474A5 true JP2022008474A5 (https=) | 2022-01-20 |
Family
ID=57006450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551164A Expired - Fee Related JP6985151B2 (ja) | 2015-04-02 | 2016-03-31 | プロトキシン−ｉｉ変異体及びその使用方法 |
| JP2021153626A Withdrawn JP2022008474A (ja) | 2015-04-02 | 2021-09-21 | プロトキシン－ｉｉ変異体及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551164A Expired - Fee Related JP6985151B2 (ja) | 2015-04-02 | 2016-03-31 | プロトキシン−ｉｉ変異体及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10463714B2 (https=) |
| EP (2) | EP3277304B1 (https=) |
| JP (2) | JP6985151B2 (https=) |
| KR (1) | KR20170134542A (https=) |
| CN (1) | CN107921089A (https=) |
| AR (1) | AR104173A1 (https=) |
| AU (2) | AU2016242905B2 (https=) |
| BR (1) | BR112017020896A2 (https=) |
| CA (1) | CA2981336A1 (https=) |
| ES (1) | ES2888799T3 (https=) |
| IL (2) | IL254599B (https=) |
| MA (1) | MA41864A (https=) |
| MX (1) | MX2017012654A (https=) |
| TW (1) | TW201708249A (https=) |
| UY (1) | UY36602A (https=) |
| WO (1) | WO2016161100A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10414808B2 (en) | 2012-05-18 | 2019-09-17 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| MX2016004282A (es) | 2013-10-03 | 2016-10-12 | Janssen Biotech Inc | Variantes de protoxina-ii y metodos de uso. |
| MA41642A (fr) | 2015-03-03 | 2018-01-09 | Janssen Biotech Inc | Variants de protoxine ii et méthodes d'utilisation |
| EP3277304B1 (en) | 2015-04-02 | 2021-08-04 | Janssen Biotech, Inc. | Protoxin-ii variants and methods of use |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CN109369784B (zh) * | 2018-11-14 | 2019-08-30 | 青海芬陀利华生物科技有限公司 | PaTx-1毒素及其应用 |
| US20230241259A1 (en) * | 2020-06-10 | 2023-08-03 | Memorial Sloan Kettering Cancer Center | IMAGING COMPOUNDS SELECTIVE FOR NaV1.7 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
| US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
| WO1998046722A1 (en) | 1997-04-16 | 1998-10-22 | Unigene Laboratories Inc. | Direct expression of peptides into culture media |
| IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
| PT1015576E (pt) | 1997-09-16 | 2005-09-30 | Egea Biosciences Llc | Metodo para a sintese quimica completa e montagem de genes e de genomas |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US20030148273A1 (en) * | 2000-08-26 | 2003-08-07 | Shoulian Dong | Target enrichment and amplification |
| EP1348466A3 (en) | 2002-02-01 | 2003-10-29 | Inspire Pharmaceuticals, Inc. | Method for treating pain with adenosine-tetraphosphates |
| US7659082B2 (en) | 2002-02-19 | 2010-02-09 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| CA2626584A1 (en) | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
| WO2007109324A2 (en) | 2006-03-21 | 2007-09-27 | Xenon Pharmaceuticals, Inc. | Potent and selective nav 1.7 sodium channel blockers |
| US8283318B2 (en) | 2006-09-08 | 2012-10-09 | Mayo Foundation For Medical Education And Research | Aquaretic and natriuretic polypeptides lacking vasodilatory activity |
| US7998980B2 (en) | 2006-09-15 | 2011-08-16 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| PE20081140A1 (es) | 2006-10-25 | 2008-09-22 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
| CN102202677A (zh) | 2008-09-03 | 2011-09-28 | 阿尔伯维塔公司 | 治疗疼痛的活性剂和方法 |
| WO2010104115A1 (ja) | 2009-03-10 | 2010-09-16 | 独立行政法人産業技術総合研究所 | 膜タンパク質を特異的に認識するポリペプチドの調製方法 |
| AU2010296994B2 (en) | 2009-09-15 | 2013-09-19 | Alomone Preclinical Ltd. | Novel peptides isolated from spider venom, and uses thereof |
| AU2011224534B2 (en) | 2010-03-08 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Full COLD-PCR enrichment with reference blocking sequence |
| US9279003B2 (en) | 2010-07-07 | 2016-03-08 | Purdue Pharma L.P. | Analogs of sodium channel peptide toxin |
| CN101979411A (zh) | 2010-10-21 | 2011-02-23 | 湖南师范大学 | 虎纹捕鸟蛛蛋白酶抑制剂 |
| JP2014507136A (ja) | 2011-01-18 | 2014-03-27 | アムジエン・インコーポレーテツド | ＮａＶ１．７ノックアウトマウスとそれらの使用 |
| KR20210056458A (ko) * | 2011-05-04 | 2021-05-18 | 바이오셉트 인코포레이티드 | 핵산 서열 변이체를 검출하는 방법 |
| CA2873860A1 (en) | 2012-05-18 | 2013-11-21 | Janssen Biotech, Inc. | Huwentoxin-iv variants and methods of use |
| US10414808B2 (en) | 2012-05-18 | 2019-09-17 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| US9102751B2 (en) | 2012-05-18 | 2015-08-11 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| US9718865B2 (en) | 2012-07-27 | 2017-08-01 | Purdue Pharma L.P. | Sodium channel blocking peptides and the use thereof |
| WO2014165277A2 (en) | 2013-03-12 | 2014-10-09 | Amgen Inc. | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 |
| CN104065367B (zh) | 2013-03-20 | 2017-11-07 | 江苏多维科技有限公司 | 一种低功耗磁电阻开关传感器 |
| MX2016004282A (es) * | 2013-10-03 | 2016-10-12 | Janssen Biotech Inc | Variantes de protoxina-ii y metodos de uso. |
| MA41642A (fr) | 2015-03-03 | 2018-01-09 | Janssen Biotech Inc | Variants de protoxine ii et méthodes d'utilisation |
| EP3277304B1 (en) | 2015-04-02 | 2021-08-04 | Janssen Biotech, Inc. | Protoxin-ii variants and methods of use |
-
2016
- 2016-03-31 EP EP16774187.5A patent/EP3277304B1/en active Active
- 2016-03-31 MA MA041864A patent/MA41864A/fr unknown
- 2016-03-31 WO PCT/US2016/025247 patent/WO2016161100A1/en not_active Ceased
- 2016-03-31 EP EP21189427.4A patent/EP3960757A1/en not_active Withdrawn
- 2016-03-31 AU AU2016242905A patent/AU2016242905B2/en not_active Ceased
- 2016-03-31 CN CN201680020883.XA patent/CN107921089A/zh active Pending
- 2016-03-31 ES ES16774187T patent/ES2888799T3/es active Active
- 2016-03-31 JP JP2017551164A patent/JP6985151B2/ja not_active Expired - Fee Related
- 2016-03-31 MX MX2017012654A patent/MX2017012654A/es unknown
- 2016-03-31 CA CA2981336A patent/CA2981336A1/en not_active Abandoned
- 2016-03-31 BR BR112017020896A patent/BR112017020896A2/pt not_active Application Discontinuation
- 2016-03-31 TW TW105110361A patent/TW201708249A/zh unknown
- 2016-03-31 KR KR1020177031290A patent/KR20170134542A/ko not_active Withdrawn
- 2016-04-01 AR ARP160100893A patent/AR104173A1/es not_active Application Discontinuation
- 2016-04-04 UY UY0001036602A patent/UY36602A/es unknown
- 2016-04-04 US US15/090,328 patent/US10463714B2/en not_active Expired - Fee Related
-
2017
- 2017-09-19 IL IL254599A patent/IL254599B/en active IP Right Grant
-
2019
- 2019-11-04 US US16/673,750 patent/US11083776B2/en not_active Expired - Fee Related
-
2021
- 2021-04-21 IL IL282508A patent/IL282508A/en unknown
- 2021-08-09 US US17/397,586 patent/US20220054590A1/en not_active Abandoned
- 2021-09-21 JP JP2021153626A patent/JP2022008474A/ja not_active Withdrawn
- 2021-11-12 AU AU2021266345A patent/AU2021266345A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022008474A5 (https=) | ||
| US11306124B2 (en) | Agonist agents of CD47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death | |
| CN102143970A (zh) | α-促黑素细胞激素的肽类似物 | |
| ES2544573T3 (es) | Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor | |
| JP2011510019A5 (https=) | ||
| CN101511873B (zh) | 用于抑制神经递质分泌的融合多肽和递送该融合多肽的方法 | |
| US8546321B2 (en) | IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases | |
| JP2010504336A5 (https=) | ||
| JPH07508025A (ja) | インスリン様増殖因子（ｉｇｆ−１）類似体 | |
| NZ337955A (en) | Modified TNF-alpha and their use as vaccines | |
| US20100099609A1 (en) | eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | |
| IL106271A (en) | Ligand to TNF 75P receptor and its preparation | |
| CN108350032A (zh) | 调节γC-细胞因子活性 | |
| JPH02188600A (ja) | Ｂｓｆ↓２アンタゴニスト | |
| Park et al. | Synthesis and biological evaluation of peptide-derived TSLP inhibitors | |
| EP0648783B1 (en) | TNF inhibitors | |
| WO2004048401A1 (ja) | ペプチド及びこれを含む医薬組成物 | |
| US8470964B2 (en) | Peptides derived from NCAM (FGLs) | |
| CN116813701B (zh) | 靶向肌肉型乙酰胆碱受体的肽分子及其制备方法、用途 | |
| Liu et al. | New peptides structurally related to VEGF-A165 exon-7 and-8 encoded domains antagonize its binding to NRP-1 and VEGF-R1 | |
| EP3333184A1 (en) | Compositions and methods for inhibiting cd279 interactions | |
| Ye et al. | Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging | |
| US10421785B2 (en) | Delta receptor agonist peptides and use thereof | |
| JP2008524173A (ja) | 新規な多量体ｃｄ４０リガンド、その製造方法及び医薬を製造するためのそれらの使用 | |
| CN101027319A (zh) | 肝素结合肽 |